Substance and claimed effects

The substance is daylight reaching the eyes — the photic input the retina gets from being outdoors under sky, distinct from indoor electric lighting. Typical illuminance gap: well-lit office ≈ 300–500 lux; overcast outdoor ≈ 10,000 lux; direct sun ≈ 50,000–100,000 lux (Wright 2013, Cajochen 2000). The same number of "hours of light" indoors and outdoors are not the same biological input.

Claimed effects, all in scope for this entry: (1) slowed myopia onset and progression in children; (2) reduced ocular-surface strain and dry-eye symptoms in screen-heavy adults, balanced against cumulative UV-mediated ocular surface damage (pterygium, photokeratitis, lens opacities); (3) circadian phase anchoring via ipRGC → SCN signalling, with downstream effects on sleep onset, sleep depth, and daytime alertness; (4) improved mood and lower depression incidence, including but not limited to seasonal affective disorder. Vitamin D synthesis is excluded — it operates through the skin, not the eye, and warrants its own entry.

Evidence by addressing question

mechanism

Science / mechanism — myopia. Animal and human work converges on a retinal dopamine model: bright light activates retinal dopamine release; dopamine acts via D2-like receptors on inner-retinal circuits to suppress axial elongation of the eye (Feldkaemper & Schaeffel 2013). Form-deprivation myopia in chicks and primates is blunted by dopamine agonists and worsened by antagonists; the dose-response between retinal illuminance and dopamine is log-linear. The implication: indoor light (100–500 lux) sits orders of magnitude below the levels at which retinal dopamine release plateaus. Spectral content (UV/violet) may contribute via OPN5 photoreceptors, but the dominant signal in human data is intensity, not wavelength.

Science / mechanism — circadian. Intrinsically photosensitive retinal ganglion cells (ipRGCs), containing melanopsin, project to the suprachiasmatic nucleus and entrain the master clock. The system is dose-responsive: dim light (<30 lux) gives <50% melatonin suppression at night in most people but >300 lux saturates the alerting response by day (Cajochen 2000, Phillips 2019). Morning daylight advances the phase of the SCN, compressing the gap between sleep onset and "biological night start." Camping studies in real wilderness conditions collapse circadian phase by ~2 hours within a week (Wright 2013, Stothard 2017).

Science / mechanism — mood. Two mechanisms operate in parallel. (1) Circadian: phase-advanced, higher-amplitude rhythms correlate with lower depression scores; daytime light raises rhythm amplitude. (2) Direct neurochemical: jugular-vein sampling shows that brain serotonin turnover rises with prevailing bright-sunlight duration (Lambert 2002). Light therapy at 10,000 lux for ~30 min/day clinically replicates this — effect sizes for seasonal and non-seasonal depression match SSRIs in head-to-head trials (Golden 2005).

Mechanism — ocular surface. Indoor near-work and screen use depress blink rate from ~15/min to ~5/min, drying the tear film. Going outdoors typically displaces near-work and resets blink behaviour. Counter-mechanism: UV-B exposure damages limbal stem cells and conjunctival fibroblasts, driving pterygium and pinguecula formation over decades; reflected UV from snow, water, sand amplifies this (Modenese & Gobba 2018). The net effect on the ocular surface depends on UV protection: outdoor time with brimmed hat / sunglasses is net-positive; equivalent time without protection in high-UV settings is net-negative for the surface, though still positive for the retinal-dopamine and circadian channels.

evidence

Myopia — RCT evidence. Three completed randomized trials in children. Wu 2013: Taiwan, two suburban schools, ~570 children 7–11; the intervention school required outdoor recess. Over 1 year, new-myopia incidence was 8.4% in the intervention school vs 17.6% in control. He 2015: Guangzhou, cluster-RCT of 1,903 first-graders across 12 schools; one extra 40-min outdoor class daily for 3 years. Cumulative new-myopia incidence 30.4% (intervention) vs 39.5% (control), absolute risk reduction 9.1% (95% CI 4.1–14.1, p<.001). Cao 2020 pooled 5 RCTs (n = 3,014): risk ratio for new myopia 0.76 (95% CI 0.67–0.87), axial-length progression reduced 0.03 mm/year, I²=0% (rare for myopia literature). The Sydney Myopia Study (Rose 2008) found that 6- and 12-year-olds doing >2 h/day outdoors had myopia prevalence roughly half that of children doing <1 h/day, independent of near-work hours. Meta-analysis dose-response: each additional hour outdoors per week → ~2% reduced odds of myopia (Xiong 2017). Trial intensity threshold appears to be cumulative — most interventions tested ≥40 min/day, no trial tested <30 min.

Myopia — caveat on progression vs onset. The cleanest signal is on onset. Xiong 2017 reports outdoor time does not slow progression in already-myopic children — the dopamine signal appears to act on the emmetropization window, not on established axial elongation. Practical reading: outdoor time prevents children from becoming myopic; for kids already in glasses, atropine + outdoor time is the protocol now used in Asian myopia clinics.

Circadian — entrainment evidence. Wright 2013 measured dim-light melatonin onset (DLMO) before and after a week of camping (no electric light); DLMO advanced ~2 hours, sleep timing followed. Stothard 2017 replicated in winter (9 h:14 h day:night) and showed weekend camping alone collapses half the phase delay from modern life. UK Biobank free-living data: each additional hour outdoors per day → earlier chronotype, shorter sleep latency, fewer reported "insomnia symptoms" (Burns 2021, n>400,000).

Mood — observational + RCT. Burns UK Biobank: each additional hour of outdoor time → reduced incidence of "feeling down", lower antidepressant use, higher self-rated happiness; the longitudinal cross-lagged design rules out reverse causation (more depressed people staying indoors) as the sole driver (Burns 2021). Light-therapy RCTs (10,000 lux box, ~30 min) for SAD and non-seasonal depression: pooled effect size ~0.84 for SAD, ~0.53 for non-seasonal depression — equivalent to antidepressant pharmacotherapy (Golden 2005). The light-therapy literature is the strongest indirect evidence for outdoor daylight's mood effect; the only difference is delivery format.

Ocular surface — observational. No RCTs on outdoor time and dry eye specifically; the evidence is mechanistic (blink rate physiology). For UV-driven surface disease, Modenese & Gobba's systematic review of 29 studies (2008–2018): outdoor workers have OR 2–7 for pterygium depending on latitude; WHO attributes 42–74% of pterygium burden to solar UV (Modenese & Gobba 2018). Cataract and age-related macular degeneration have weaker but consistent UV-exposure associations.

protocol

Effective doses derived from trial evidence and circadian dose-response:

• Children (myopia): ≥40 minutes of outdoor time daily (school + post-school) is the trial-tested floor that delivers a 9% absolute risk reduction over 3 years (He 2015). The Sydney data suggests 2 hours/day is where the prevalence curve flattens (Rose 2008). Outdoor time is what matters; sports vs unstructured play vs walking school commute appear equivalent — the variable is retinal illuminance, not activity type.
• Adults (circadian): ≥10–30 minutes of morning outdoor light, within ~1 hour of waking, drives the largest phase-anchoring signal (Wright 2013). Overcast outdoor light (~10,000 lux) is sufficient — sunlight is not required. The dose for alerting saturates around ~1,000 lux during the day (Cajochen 2000), so any meaningful outdoor exposure exceeds it.
• Adults (mood): The light-therapy analogue is 10,000 lux for 30 minutes (Golden 2005). Overcast outdoor matches this; mid-day sun delivers it in <5 minutes. Each additional hour outdoors/day in UK Biobank → small but real reduction in depressed-mood symptoms (Burns 2021).
• UV protection: Brimmed hat and UV-blocking sunglasses for any sun exposure beyond ~30 minutes; mandatory for snow, water, high-altitude, or low-latitude environments. Sunglasses do not block enough light to defeat the circadian or dopamine signal — retinal illuminance through standard sunglasses outdoors still vastly exceeds indoor levels.

contraindications

Few. Photic-sensitive epilepsy and photosensitive lupus / xeroderma pigmentosum need clinician input. Lens-replacement surgery patients without UV-filtering implants should be cautious with direct mid-day sun. Otherwise universally indicated — the population deficit is overwhelmingly under-exposure, not over-exposure.

misconceptions

(1) "Sitting by a window counts." Window glass attenuates outdoor illuminance roughly 10×; a "bright" window seat is typically 1,000–3,000 lux vs 10,000+ outdoors. Glass also blocks most UV-B, which removes the spectral component that drives some of the dopamine signal in animal models. The myopia trials specifically measured time outdoors, not "near a window." (2) "Indoor lighting is enough — modern offices are bright." Modern office design targets ~500 lux at desk height; even a daylight-balanced "circadian lighting" install rarely exceeds 1,500 lux. The biological gap to outdoors is 1–2 orders of magnitude (Wright 2013). (3) "Sunglasses cancel the benefit." Standard sunglasses transmit 5–25% of incident light. Outdoor light through sunglasses is still 500–25,000 lux — above the indoor baseline. The myopia trials did not control sunglasses use and saw the effect anyway. (4) "Screen time is the cause of myopia." Near-work correlates with myopia but in multivariate models, outdoor time is the stronger and independent predictor (Rose 2008). Children who do lots of near-work AND lots of outdoor time have lower myopia than children who do less of both.

audience

Children (≤14): Myopia channel dominates. Asian-ethnicity children are the worst-affected population — myopia prevalence in urban East Asia exceeds 80% in young adults, vs ~40% in equivalent Australian-of-East-Asian-descent samples, the gap attributed largely to differing childhood outdoor time (Rose 2008). Trial-grade evidence is densest here.

Adults (18–59): Circadian + mood + alertness channels dominate; ocular-surface channel relevant for screen workers. Daylight competes with the work pattern of most knowledge workers, which is the practical bottleneck.

Older adults (60+): Same circadian + mood gains, plus lens-aging means less UV reaches the retina, which means a higher outdoor dose may be needed for the same biological effect. UV protection becomes more important because lens opacities accumulate; cataract risk rises with cumulative ocular UV.

Night-shift workers: Outdoor light timing inverts. Morning outdoor light after a night shift will keep them entrained to a day schedule they don't live; targeted bright light during the work shift and dark sunglasses on the commute home are the protocol — see chronobiology references, outside this entry's primary scope.

failure-modes

(1) Walking the dog at 7am with sunglasses + hood up. The intent is right but the retinal dose is much lower than the user thinks. (2) Reading near a window for an hour. Lux through glass is far short of trial-tested doses. (3) "I get outside on weekends." Two big weekend doses cannot replace weekday entrainment — the SCN is anchored by the daily light signal, not weekly totals (Stothard 2017). (4) Excessive UV without protection. Pterygium, photokeratitis ("snow blindness"), accelerated cataract — visible at tropical-latitude outdoor workers. (5) Children sent outside but staying under a covered awning. Shaded outdoor is intermediate (~5,000 lux) — better than indoors but lower-dose than open sky.

stakes

Stakes evidence comes from inversion of the same data. UK Biobank shows that the lowest tertile of outdoor-time exposure has 13% higher odds of "frequent feelings of being down" and 17% higher use of antidepressants vs the highest tertile, after adjustment for age, sex, socioeconomic status, employment, and sleep duration (Burns 2021). The myopia epidemic in urban East Asia — projected 50% of world population myopic by 2050 — is the macroscopic stakes case for the child population.

payoff

Sleep-onset latency, sleep-depth, and self-rated mood are the fastest channels (days to a week, consistent with circadian phase-anchoring time constants — Wright 2013, Stothard 2017). Mood lift from light therapy stabilises by week 2–3 (Golden 2005). Myopia delay shows over years, not months — visible only in cohort comparisons. Cumulative-aesthetic gains (less screen-strain redness, fewer dark-circle markers from poor sleep) ride on the sleep and mood improvements; they are second-order and modest.

out-of-scope

Vitamin D synthesis (skin, not eye — separate entry); skin-mediated dermatological effects of UV (tanning, photoaging, skin cancer); the broader argument for time-in-nature beyond light specifically (green-space and stress, microbiome diversity from outdoor environments); seasonal affective disorder treatment specifically (own entry would be warranted); light-therapy boxes as an indoor proxy.

Credibility range

Optimist case. The myopia RCT evidence is rare in lifestyle medicine: multiple trials, consistent direction, dose-response, mechanism (dopamine) validated in animal models, meta-analysis with I²=0%. The circadian evidence is similarly tight — camping studies are essentially within-subject experiments showing the natural light-dark cycle resets the clock. UK Biobank gives 400,000-person longitudinal mood data with cross-lagged design controlling reverse causation. Pull these together and the case is: indoor-only modern life is a chronic, population-scale photic deficiency, and reversing it is one of the highest-leverage zero-cost interventions in the catalogue.

Skeptic case. The myopia mechanism question is unsettled — the dopamine model fits animal data but human ipRGC/dopamine pathways are inferred, not directly measured. Outdoor time confounds with physical activity, near-work reduction, social interaction, and vitamin D; isolating "eye-light" from these in observational data is hard, and the RCTs intervened on the bundle, not the photons. UK Biobank effect sizes for mood are small (odds-ratio differences of 1.1–1.2), and self-reported outdoor time is noisy. The light-therapy RCTs use 10,000-lux boxes for 30 min, which is a much more controlled exposure than "go outside for a walk" — generalisation is plausible, not proven. Pterygium and lens damage are real cumulative costs that the optimist case underweights.

Author's call. The intervention is real, the direction is robust, the magnitude is moderate-to-large for circadian and myopia, moderate for mood, and the cost is zero. Even granting the skeptic's confounds, the floor on benefit (circadian phase anchoring, dopamine signal in children) is well-supported and the ceiling on harm with sane UV protection is low. The right framing is not "miracle cure" — it's "modern indoor life is a deficiency state, and going outdoors is the correction." Evidence rating: 4. Controversy: 1 (low — the field agrees on direction; debates are about magnitude and mechanism specifics).

Stakeholder and incentive map

• Pushing the intervention: Pediatric ophthalmology (myopia epidemic is the field's defining public-health crisis); circadian researchers and the broader light-and-health consortium (CIE, DIN, IES committees publishing new daylight-design standards); chronobiology academia (Czeisler, Wright, Cain labs); public-health bodies in East Asia where myopia has reached national-emergency status (Taiwan, Singapore, China school-recess mandates).
• Pushing back / inertia: Commercial real-estate and office-design conventions optimised around artificial-light cost minimisation; screen and tech industries whose product use displaces outdoor time; supplement industry pushing vitamin D and other proxies for "what you'd get outside"; dermatology messaging emphasising sun avoidance for skin cancer prevention (which is correct but creates tension with eye-and-circadian benefits).
• Neutral commercial: Lighting industry — the high-end of the market is moving toward "circadian lighting" / "human-centric lighting" but indoor-only systems still fall short of outdoor by 1–2 orders of magnitude, so claims that "our lights replace sunshine" should be discounted.

Population variability

• Latitude and season. Winter at high latitudes (Scandinavia, northern Canada) provides few hours of outdoor light and lower midday illuminance — the deficit case is most acute there, and light-therapy box use is most appropriate.
• Ethnicity. East Asian children show the highest myopia risk and the largest absolute benefit from outdoor intervention (Rose 2008). Darker iris pigmentation moderately reduces retinal illuminance for the same external lux; effect on dopamine signal is unclear.
• Age. Lens yellowing with age reduces short-wavelength light reaching ipRGCs and retinal dopamine cells; older adults may need higher outdoor doses for equivalent circadian or mood effect.
• Individual circadian sensitivity. Phillips 2019 found >50-fold interindividual variability in melatonin suppression response to evening light. The same likely applies to daytime phase-anchoring sensitivity: some people will get sleep improvement from a 15-minute morning walk, others need an hour.
• Baseline circadian disruption. Shift workers, frequent travellers, depressed patients — these populations are operating with disrupted rhythms and have more to gain from a daily outdoor-light anchor than the already-entrained.

Knowledge gaps

• Mechanism of myopia. Dopamine is the leading candidate but precise circuit detail in humans is missing; whether intensity, spectral content, or temporal variability matters most is unsettled.
• Adult myopia. Whether adult-onset myopia (progression after age 18) responds to outdoor light remains under-studied. The animal models all use developing eyes.
• Minimum effective dose for circadian effects in free-living adults. Most data come from extreme contrasts (camping vs office); the dose-response curve for "30 vs 60 vs 90 min daily" in normal life is sparse.
• Long-term mood RCTs. Light therapy is RCT-proven; "go outside more often" RCTs in mood are operationally hard and mostly absent. The mood evidence is observational + analogue.
• Net ocular-surface effect. No trial compares "outdoor time with eyewear protection" against "matched indoor time" for dry-eye or surface health.
• What would change the call. A failed adult outdoor-light RCT for sleep or mood would lower the rating. A failed long-term myopia follow-up showing rebound (some signal of this in Wu's 4-year follow-up) would soften the child recommendation. Confirmation of an OPN5-mediated, spectrum-specific pathway would change protocol-specific advice but not the directional call.

Scope. Brief named four consequences (myopia, ocular-surface, circadian, mood). All four covered:

• Myopia in children — full audience, evidence, payoff coverage. Strongest evidence in the entry.
• Circadian rhythm — backbone of mechanism, evidence, protocol, drives the sleep-4 score.
• Mood — covered in evidence, stakes, payoff via Burns 2021 + Lambert 2002 + Golden 2005.
• Ocular surface health — narrower coverage than the others. Folded into contraindications as the UV-cost side and gestured at in misconceptions. No RCT evidence for outdoor-time → dry-eye relief specifically; the dry-eye mechanism (blink rate) is real but unproven as a daylight-eye-exposure outcome. Resisted padding this into its own addressing section.

Hard scoping calls.

• Vitamin D excluded. Skin-route, not eye-route. Different photoreceptor, different organ, different protocol (UV-B vs visible light), different contraindication profile. Belongs in a separate vitamin-d entry. Flagged in out-of-scope.
• Evening light hygiene excluded. The dark side of the circadian pair. Phillips 2019 is the load-bearing study there. Should be its own entry — flagged in out-of-scope.
• Light-therapy boxes excluded as a primary topic. They are the strongest mood evidence we have, but they're an indoor proxy, not the substance. Used as analogue evidence in the evidence section; mentioned as a winter fallback in failure-modes and out-of-scope. A dedicated light-therapy entry is warranted.
• Skin sun exposure / tanning / photoaging excluded. Different substance.

Rating difficulties.

• longevity 2 vs 3 was the closest call. The mechanism-to-mortality chain runs through sleep + mood + (in children) myopia complications. Cohort signals exist but are confounded with physical activity and vitamin D. Landed on 2 because outdoor-time RCTs measure proximal endpoints, not mortality.
• mood 4 vs 5: the light-therapy evidence (Golden 2005) is RCT-grade and SSRI-equivalent for SAD, which arguably justifies a 5. Landed on 4 because the outdoor-light evidence is largely observational; the box is the controlled proxy. Reserve 5 for entries where direct RCTs on the substance itself match the 5 anchor.
• evidence 4: strong RCTs on myopia, controlled experiments on circadian, observational + light-therapy proxy on mood. The mood story is the weakest link; if a large outdoor-time RCT for mood lands, this could move to 5.
• beauty_direct scored 0 (rather than 1). Eye-route daylight does not produce a within-days visible-skin effect; the only candidate (less screen-strain redness) is too marginal to score above 0.

Future-link candidates (entries not yet in the catalogue that this entry should cross-link once they exist).

• vitamin-d — skin-route sun + supplementation
• evening-light-hygiene or dark-bedroom — the circadian bookend
• light-therapy-box — winter and indoor-bound fallback
• myopia-management — for already-myopic children: atropine, orthokeratology, multifocal lenses
• shift-work-and-circadian — population for whom standard "morning outdoor light" advice is wrong

Separate-entry candidates surfaced while writing. Seasonal affective disorder treatment specifically (light-therapy protocol, dawn simulation, comparison with SSRIs) is substantial enough to deserve its own entry rather than living as a paragraph here.